Floatz logo

FLUTICASONE

Metastatic Adenocarcinoma

University of California, DavisSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Metastatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
University of California, Davis
Phase 1/2CCC

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →